Related Experiment Video
Updated: Feb 26, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
23.3K
Ruthenium-conjugated chrysin analogues modulate platelet activity, thrombus formation and haemostasis with enhanced
Divyashree Ravishankar1, Maryam Salamah1, Alda Attina1
1School of Pharmacy, University of Reading, Reading, UK.
Scientific Reports
|July 20, 2017
Summary
New ruthenium-chrysin compounds significantly inhibit platelet function and thrombus formation. Ru-thio-chrysin shows enhanced efficacy compared to chrysin, offering potential for novel anti-thrombotic therapies.
Area of Science:
- Pharmacology
- Biochemistry
- Cardiovascular Research
Background:
- Cardiovascular disease rates are rising, necessitating improved therapeutic strategies due to limitations of current treatments.
- Natural flavonoids possess diverse pharmacological properties beneficial for human health.
- Chrysin, a flavonoid found in honey and passionflower, influences platelet function, hemostasis, and thrombosis.
Purpose of the Study:
- To evaluate the anti-thrombotic potential of chrysin and its derivatives.
- To enhance chrysin's efficacy by synthesizing sulfur and ruthenium derivatives.
- To investigate the effects of novel compounds on platelet function, hemostasis, and thrombosis.
Main Methods:
- Synthesis of thio-chrysin, Ru-chrysin, and Ru-thio-chrysin.
- Assessment of platelet function inhibition in isolated platelets, platelet-rich plasma, and whole blood.
- Evaluation of hemostasis modulation in a mouse model.
- Analysis of bioavailability and cell permeability.
Main Results:
- Chrysin showed inhibitory effects on isolated platelets, but activity decreased under physiological conditions.
- Ru-thio-chrysin demonstrated a 4-fold greater inhibition of platelet function and thrombus formation in vitro compared to chrysin under physiological conditions.
- Ru-thio-chrysin exhibited comparable efficacy to chrysin in modulating hemostasis in mice.
- Enhanced bioavailability and cell permeability of Ru-thio-chrysin contributed to its increased activity.
Conclusions:
- Ru-thio-chrysin is a potent inhibitor of platelet function and thrombus formation.
- Ruthenium-coupled thio-chrysin derivatives represent promising candidates for developing novel anti-thrombotic agents.
- Natural compounds like chrysin, when modified, can lead to significantly improved therapeutic efficacy.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:22Formation of the Platelet Plug
10.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.0K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
546
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
546